Novel Therapeutic Approaches for Aggressive Prostate Cancer
侵袭性前列腺癌的新治疗方法
基本信息
- 批准号:10734381
- 负责人:
- 金额:$ 38.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenocarcinomaAggressive behaviorBindingCellsChemoresistanceClinicClinical TrialsCoupledDataGoalsImmuneImmune EvasionImmune checkpoint inhibitorImmune responseImmunocompetentImmunosuppressionInvadedMalignant NeoplasmsMalignant neoplasm of prostateMediatingMetastatic Prostate CancerModelingMonoclonal AntibodiesMorbidity - disease rateMusNPR2 geneNeoplasm MetastasisNeuroendocrine Prostate CancerNeuroendocrine TherapyNeuropilin-2OutcomePhenotypePredispositionPropertyReportingResistanceRoleSignal TransductionTherapeuticToxic effectTumor BurdenTumor ImmunityTumor PromotionUp-RegulationVascular Endothelial Growth FactorsWorkadvanced prostate cancerautocrinecell killingcheckpoint inhibitionchemotherapyeffective therapyexosomehumanized antibodyimprovedinhibitormanufacturemortalityneoplastic cellnonhuman primatenovelnovel therapeutic interventionpressureprogrammed cell death ligand 1programmed cell death protein 1prostate cancer modelreceptorresponsestem cellsstemnesstherapeutic targettranslational potentialtreatment strategytumortumor progression
项目摘要
Summary
The goal of this proposal is to develop a novel therapeutic strategy for the treatment of neuroendocrine
prostate cancer (NEPC) that has the potential for translation to the clinic. NEPC is an aggressive form of
prostate cancer that is associated with rapid progression, resistance to treatments and a very poor outcome.
Currently, there are no effective therapies for treating NEPC. This revised proposal focuses on the hypothesis
that programmed cell death 1 ligand (PD-L1) has a causal role in the stemness and metastatic propensity
associated with NEPC. Although PD-L1 is best known for its role in immune suppression, its tumor cell
intrinsic functions that are independent of immune suppression can also contribute to cancer progression.
Specifically, PD-L1 has been implicated in tumor stemness, invasion and metastasis and there is
circumstantial evidence that it contributes to these functions in NEPC, although a causal role has yet to be
demonstrated. This novel function of PD-L1 can be exploited to improve the therapy of NEPC based on
compelling evidence that VEGF/NRP2 signaling sustains the expression of PD-L1 in prostate cancer.
Inhibiting VEGF/NRP2 reduces stem cell properties and promotes a more differentiated phenotype that is more
susceptible to chemotherapy, and it is likely that the mechanism involves reducing PD-L1 expression. Also, a
humanized mAb is available that inhibits the binding of VEGF to NRP2. This mAb does not cause toxicity in
mice and non-human primates and is being manufactured for use in clinical trials. Of note, this mAb diminishes
the expression of PD-L1 significantly in models of NEPC. Together, these observations formulate a central
hypothesis: PD-L1 has a causal role in NEPC by sustaining stemness and facilitating metastasis (cell
autonomous PD-L1 function) and by promoting immune cell evasion (non-cell autonomous PD-L1 function).
Both critical functions of PD-L1 can be blocked by therapeutic targeting of VEGF binding to NRP2 to improve
the morbidity and mortality associated with NEPC. The first specific aim will investigate a therapeutic strategy
for inhibiting tumor cell intrinsic functions of PD-L1 to mitigate stemness and metastasis in NEPC that involves
blocking the binding of VEGF to NRP2. The second aim will investigate therapeutic strategies that target PD-
1-dependent and PD-1-independent functions of PD-L1 in NEPC by blocking the binding of VEGF to NPR2
using immune competent models. The data generated in this proposal have the potential to provide sufficient
evidence to justify the initiation of clinical trials using NRP2 inhibitors, especially the function-blocking Abs that
are the focus of the experimental approach.
摘要
这项提议的目标是开发一种治疗神经内分泌的新策略。
前列腺癌(NEPC)有可能转化为临床。NEPC是一种具有侵略性的形式
前列腺癌与进展快、治疗抵抗和预后非常差有关。
目前,还没有有效的治疗方法来治疗NEPC。这项修订后的提案侧重于假设
程序性细胞死亡1配体(PD-L1)在干细胞分化和转移倾向中起因果作用
与NEPC相关联。尽管PD-L1因其在免疫抑制中的作用而闻名,但其肿瘤细胞
独立于免疫抑制的内在功能也可能导致癌症的进展。
具体地说,PD-L1与肿瘤的干性、侵袭和转移有关,并且有
间接证据表明,它对NEPC的这些功能有贡献,尽管因果关系尚未确定
演示了。PD-L1的这一新功能可以被开发来改善NEPC的治疗
令人信服的证据表明,血管内皮生长因子/NRP2信号支持前列腺癌中PD-L1的表达。
抑制VEGF/NRP2会降低干细胞的特性,并促进更分化的表型,即
对化疗敏感,其机制可能涉及减少PD-L1的表达。此外,还有一个
人源化单抗可以抑制血管内皮生长因子与NRP2的结合。该单抗不会对小鼠产生毒性
老鼠和非人类灵长类动物,正在制造用于临床试验。值得注意的是,这种单抗会减弱
PD-L1在NEPC模型中的表达明显增强。总而言之,这些观察形成了一个中心
假设:PD-L1通过维持干性和促进转移(细胞)在NEPC中起因果作用
自主PD-L1功能)和促进免疫细胞逃避(非细胞自主PD-L1功能)。
PD-L1的这两个关键功能可以通过治疗靶向与NRP2结合来阻断,以改善
与NEPC相关的发病率和死亡率。第一个具体目标是研究治疗策略。
为了抑制肿瘤细胞PD-L1的内在功能以减轻NEPC的干性和转移,涉及
阻断血管内皮生长因子与NRP2的结合。第二个目标是研究针对帕金森病的治疗策略。
PD-L1通过阻断VEGF与NPR2的结合在NEPC中的1依赖和PD-1非依赖性功能
使用免疫能力模型。本提案中产生的数据有可能提供足够的
使用NRP2抑制剂,特别是功能阻断抗体启动临床试验的证据
是实验方法的重点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arthur M Mercurio其他文献
Arthur M Mercurio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arthur M Mercurio', 18)}}的其他基金
Integrin Regulation of Non-apoptotic Death in Breast Cancer
整合素对乳腺癌非凋亡死亡的调节
- 批准号:
10196990 - 财政年份:2018
- 资助金额:
$ 38.32万 - 项目类别:
Integrin Regulation of Non-apoptotic Death in Breast Cancer
整合素对乳腺癌非凋亡死亡的调节
- 批准号:
10439666 - 财政年份:2018
- 资助金额:
$ 38.32万 - 项目类别:
Nanosensor-Based Phenotypic Screening for Precision Therapy of Cancer Stem Cells
基于纳米传感器的表型筛选用于癌症干细胞的精准治疗
- 批准号:
9371612 - 财政年份:2017
- 资助金额:
$ 38.32万 - 项目类别:
Mechanisms of Carcinoma Differentiation and Invasion
癌分化和侵袭的机制
- 批准号:
8658042 - 财政年份:2012
- 资助金额:
$ 38.32万 - 项目类别:
Mechanisms of Carcinoma Differentiation and Invasion
癌分化和侵袭的机制
- 批准号:
8507623 - 财政年份:2012
- 资助金额:
$ 38.32万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:














{{item.name}}会员




